Overview

Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer

Status:
Completed

Trial end date:
2010-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether irinotecan, S-1, and bevacizumab are safe in the treatment of unresectable or recurrent colorectal cancer

Phase:

Phase 2

Details

Lead Sponsor:

Taiho Pharmaceutical Co., Ltd.

Treatments:

Bevacizumab
Camptothecin
Irinotecan